公开(公告)号：US20220098303A1

公开(公告)日：2022-03-31

申请号：US17426695

申请日：2020-01-31

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Swethajit Biswas ,  Nicola A. JACKSON ,  Elaine Marie PAUL ,  Herbert STRUEMPER ,  Joanna OPALINSKA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: Disclosed herein are combinations of an antigen binding protein that binds BCMA with an antigen binding protein that bind to an immunomodulatory agent, such as PD-1 or OX40, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.

公开(公告)号：US20190023791A1

公开(公告)日：2019-01-24

申请号：US15749141

申请日：2016-08-03

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  MERCK SHARP & DOHME CORP.

Inventor： Axel HOOS ,  David KAUFMAN ,  Elaine PINHEIRO ,  Herbert STRUEMPER ,  Niranjan YANAMANDRA

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention provides methods of treating cancer in a human in need thereof comprising administering to the human: a therapeutically effective amount of a monoclonal antibody that binds to human OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; and a therapeutically effective amount of a monoclonal antibody that binds to human PD-1 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:54; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:55; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:56; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59.